Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2019

View Archived Issues

Roche presents first-in-human data for RO-7062931

HPN-328 targeting DLL3 shows preclinical efficacy and safety for immunotherapy in SCLC

New Smo antagonist shows antitumor activity in medulloblastoma and cholangiocarcinoma animal models

New PEGylated IL-2 with improved pharmacologic properties specifically activates and expands Tregs

Anchiano discontinues phase II Codex study of inodiftagene vixteplasmid in NMIBC

Positive results presented from second phase III psoriasis study of bimekizumab

Results presented from proof-of-concept phase I study of cenerimod

First-in-human data presented for tetrameric bispecific antibody AK-104

DRA inhibitors synthesized for cystic fibrosis-related nephrolithiasis

Gut bacteria can drive heart autoimmunity

Succinate identified as novel cancer therapy target

Sparsentan does not appear to have a negative effect on quality of life in FSGS patients

First-in-human data for novel platelet glycoprotein IIb/IIIa inhibitor RUC-4 in patients with STEMI

Institute for Translational Vaccinology tests RSV vaccine in phase I study

Japanese researchers patent TRPC3 and TRPC6 antagonists

Nippon Chemiphar discloses xanthine oxidase inhibitors

Innate Tumor Immunity identifies NLRP3 agonists

Korean investigators disclose mTORC1 inhibitors

New SCD1 and SCD5 inhibitors presented by Yumanity Therapeutics

Phase I trial studies Rocket's hematopoietic cell-based gene therapy for pyruvate kinase deficiency

Shanghai De Novo studies DN-1508052-01 in phase I for advanced solid tumors

FDA approves Adakveo to reduce vaso-occlusive crises in patients with sickle cell disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...